Olgu Sunumu – Antifosfolipid Sendromu

Luo L, Cai Q, Liu X, Hou Y, Li C. Risk factors of first thrombosis in obstetric antiphospholipid syndrome. Lupus Sci Med. 2024 Jan 3;11(1):e001044. doi: 10.1136/lupus-2023-001044. PMID: 38176700; PMCID: PMC10773425.

Miyakis, S.; Lockshin, M.D.; Atsumi, T.; Branch, D.W.; Brey, R.L.; Cervera, R.; Derksen, R.H.W.M.; De Groot, P.G.; Koike, T.; Meroni, P.L.; et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006, 4, 295–306.

Barbhaiya M, Zuily S, Naden R, et al. The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis Rheumatol. 2023;75(10):1687-1702. doi:10.1002/art.42624

Misasi R, Longo A, Recalchi S, et al. Molecular Mechanisms of “Antiphospholipid Antibodies” and Their Paradoxical Role in the Pathogenesis of “Seronegative APS”. Int J Mol Sci. 2020;21:8411.

Lackner KJ, Müller-Calleja N. Pathogenesis of antiphospholipid syndrome: Recent insights and emerging concepts. Expert Rev Clin Immunol. 2019;15:199–209

Radic M, Pattanaik D. Cellular and molecular mechanisms of antiphospholipid syndrome. Front Immunol. 2018;9:969.

Chaturvedi S, Braunstein EM, Yuan X, et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020;135:239–251.

Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol. 2007;196:167.e1–167.e5.

Yelnik CM, Laskin CA, Porter TF, et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med. 2016;3(1):e000131. Published 2016 Jan 12. doi:10.1136/lupus-2015-000131

Abou-Nassar K, Carrier M, Ramsay T, Rodger MA. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res. 2011;128(1):77-85. doi:10.1016/j.thromres.2011.02.006

Yamada H, Atsumi T, Kobashi G, et al. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Reprod Immunol. 2009;79(2):188-195. doi:10.1016/j.jri.2008.11.001

Ambati A, Knight JS, Zuo Y. Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach. Curr Opin Rheumatol. 2023;35(3):149-160. doi:10.1097/BOR.0000000000000932

Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498–1509.

Alijotas-Reig J, Esteve-Valverde E, Anunciación-Llunell A, Marques-Soares J, Pardos-Gea J, Miró-Mur F. Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review. J Clin Med. 2022;11(3):675. Published 2022 Jan 28. doi:10.3390/jcm11030675

Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid antibodies and fetal death. Obstet Gynecol. 1996;87(4):489-493.

Lockshin MD, Druzin ML, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol. 1989;160(2):439-443. doi:10.1016/0002-9378(89)90468-7

Hamulyák EN, Scheres LJ, Marijnen MC, Goddijn M, Middeldorp S. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst Rev. 2020;5(5):CD012852. Published 2020 May 2. doi:10.1002/14651858.CD012852.pub2